The Food and Drug Administration (FDA) issued a stark warning Tuesday about malfunctioning blood glucose monitoring devices that may have contributed to seven deaths and hundreds of serious injuries.

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...

Malfunctioning glucose trackers made by Abbott Diabetes Care have been linked to more than 700 severe adverse events and seven potential deaths, the Food and Drug Administration (FDA) and Abbott said.

Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are ...

A medical device correction has been initiated for 3 million continuous glucose monitors. Certain Freestyle Libre 3 systems may provide incorrect low glucose readings, which can lead to serious health ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories is moving to replace more than a ...

The first USB port hit the market in 1996, and the Universal Serial Bus quickly became the go-to port for connecting peripheral devices to computers. It remains a popular connection port today, with ...

Many of us use quizzes in tutorials to assess understanding. However, traditional quiz formats often function as static assessments and are disconnected from the learning process itself. Students ...

Healthcare major Abbott has launched its next-generation continuous glucose monitoring (CGM) device, the FreeStyle Libre 2 Plus, in India, offering real-time glucose readings every minute and optional ...

Pamela Anderson Responds To Meghan Markle 'Rip-Off' Drama With 1 Perfect Line Family issues warning as son dies after taking highly addictive over-the-counter supplement: ‘The government doesn’t step ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...